Bilateral anterior uveitis secondary to erlotinib

Lim, Lik Thai; Blum, Robert A.; Cheng, Chee Peng; Hanifudin, Abdul

doi:10.1007/s00228-010-0873-7

Cited by 12 publications

(15 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, drug-induced bilateral AAU is a rare entity. Four cases of erlotinib-associated AAU have been reported since 2010 8–11. The first reported case of bilateral AAU attributable to erlotinib reported in 2010 was of a 63-year-old woman in Glasgow, with no significant medical history apart from advanced NSCLC 8.…”

Section: Discussionmentioning

confidence: 99%

“…Four cases of erlotinib-associated AAU have been reported since 2010 8–11. The first reported case of bilateral AAU attributable to erlotinib reported in 2010 was of a 63-year-old woman in Glasgow, with no significant medical history apart from advanced NSCLC 8. She developed ocular symptoms (bilateral red painful eyes with photophobia and decreased visual acuity) and systemic symptoms including diarrhoea and headache after 5 weeks of erlotinib therapy 8.…”

Section: Discussionmentioning

confidence: 99%

“…The first reported case of bilateral AAU attributable to erlotinib reported in 2010 was of a 63-year-old woman in Glasgow, with no significant medical history apart from advanced NSCLC 8. She developed ocular symptoms (bilateral red painful eyes with photophobia and decreased visual acuity) and systemic symptoms including diarrhoea and headache after 5 weeks of erlotinib therapy 8. At subsequent ophthalmic review 6 weeks post-commencement of erlotinib, she was found to have bilateral AAU with almost complete posterior synechiae 8.…”

Section: Discussionmentioning

confidence: 99%

“…She developed ocular symptoms (bilateral red painful eyes with photophobia and decreased visual acuity) and systemic symptoms including diarrhoea and headache after 5 weeks of erlotinib therapy 8. At subsequent ophthalmic review 6 weeks post-commencement of erlotinib, she was found to have bilateral AAU with almost complete posterior synechiae 8. She was treated with topical ocular steroids and mydriatics for 2 weeks with resolution of the AAU and synechiae; no mention was made of interruption of erlotinib treatment 8.…”

Section: Discussionmentioning

confidence: 99%

“…At subsequent ophthalmic review 6 weeks post-commencement of erlotinib, she was found to have bilateral AAU with almost complete posterior synechiae 8. She was treated with topical ocular steroids and mydriatics for 2 weeks with resolution of the AAU and synechiae; no mention was made of interruption of erlotinib treatment 8. The second case was reported in 2011 and involved a 68-year-old woman in Liverpool with NSCLC treated with erlotinib 9 10.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib

et al. 2019

View full text Add to dashboard Cite

Erlotinib used in the treatment of advanced non-small cell lung cancer (NSCLC) is a first-generation small-molecule tyrosine kinase inhibitor which reversibly inhibits the kinase domain of epithelial growth factor receptor (EGFR). The incidence of ocular toxicities as adverse effects (AE) of erlotinib is relatively common. However, post-marketing, acute anterior uveitis (AAU) has been reported in a small number of cases as a putative AE resulting from erlotinib therapy. We present a case of a 67-year-old, Caucasian woman, lifelong non-smoker with stage IV NSCLC who presents with decreased visual acuity and ‘floaters’ 6 weeks after commencing erlotinib. She was later diagnosed with erlotinib-associated bilateral AAU. This is the fifth documented case of erlotinib-associated bilateral AAU since 2010, highlighting the rarity of this AE. Thus, the possibility of AAU should always be considered in patients on EGFR-blocking therapies as significant ocular damage can occur if ophthalmic complaints are not triaged and assessed quickly.

show abstract

Section: Discussionmentioning

confidence: 99%